{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:16:40Z","timestamp":1777785400215,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Basal cell carcinoma (BCC) is the most frequent non\u2010melanoma skin cancer. The basis of treatment is surgical resection. The treatment of locally advanced and metastatic disease is currently based on sonidegb or vismodegib, small molecule inhibitors of the hedgehog signalling pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The study aimed to retrospectively analyse the efficacy and safety of treatment with vismodegib in 108 patients with locally advanced or metastatic disease treated from August 1st, 2017 to December 31st, 2020. The primary objective was to evaluate the objective response rate (ORR), overall survival (OS) and progression\u2010free survival rates. The secondary aims of the study were the disease control rate, the incidence of adverse events (AEs) and the estimation of the factors that potentially impact the treatment outcome and patient survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients treated in national drug programme were enrolled into this retrospective cohort study. Evaluation of the treatment efficacy was performed according to CT\/MRI scans and by the response evaluation criteria in solid tumours (RECIST) 1.1. The safety evaluation was performed according to the Common Terminology Criteria for Adverse Events v. 5.0 (CTCAE) classification and severity assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median duration of treatment was 14\u2009months (range 1\u201394\u2009months). The median progression\u2010free survival reached 30.5\u2009months (95% CI; 24.8\u201336.3), and the progression\u2010free survival rate after 6, 12 and 24\u2010months were 92%, 78% and 61%, respectively. The median overall survival was 41.5\u2009months (95% CI; 31.6\u201351.3), and the overall survival rate after 1, 2 and 3\u2009years accordingly 86%, 73% and 60%. The univariant and multivariant analysis indicated that the female gender is an independent positive prognostic factor of progression\u2010free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The response to treatment is the prognostic factor for response maintenance and better overall survival. The therapy was well tolerated with the safety profile consistent in general with known from previous studies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18070","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T08:11:06Z","timestamp":1647159066000},"page":"1219-1228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma \u2013 real world multicenter cohort study"],"prefix":"10.1111","volume":"36","author":[{"given":"M.","family":"S\u0142owi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Dermatology Military Institute of Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dudzisz\u2010\u015aled\u017a","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sobczuk","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"},{"name":"Department of Experimental and Clinical Physiology Laboratory of Centre for Preclinical Research Medical University of Warsaw Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5426-2725","authenticated-orcid":false,"given":"I.","family":"\u0141asi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Medical and Experimental Oncology Heliodor \u015awi\u0119cicki Clinical Hospital Pozna\u0144 University of Medical Sciences Pozna\u0144 Poland"},{"name":"Department of Nursing Institute of Medical Sciences Collegium Medicum University of Zielona G\u00f3ra Zielona G\u00f3ra Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pietruszka","sequence":"additional","affiliation":[{"name":"1st Radiation and Clinical Oncology Department Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Gliwice Branch Gliwice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Cybulska\u2010Stopa","sequence":"additional","affiliation":[{"name":"Clinical Oncology Department Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Cracow Branch Cracow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kowalczyk","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy Medical University of Gda\u0144sk Gda\u0144sk Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"\u015awitaj","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Department of Dermatology Military Institute of Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kose\u0142a\u2010Paterczyk","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rogala","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Paluchowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology Military Institute of Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sk\u0142adowski","sequence":"additional","affiliation":[{"name":"1st Radiation and Clinical Oncology Department Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Gliwice Branch Gliwice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mackiewicz","sequence":"additional","affiliation":[{"name":"Department of Medical and Experimental Oncology Heliodor \u015awi\u0119cicki Clinical Hospital Pozna\u0144 University of Medical Sciences Pozna\u0144 Poland"},{"name":"Department of Diagnostics and Cancer Immunology Greater Poland Cancer Centre Pozna\u0144 Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Owczarek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Military Institute of Medicine Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.060"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.09.004"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.12.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14780"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0780"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.012"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00794"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113713"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.021"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70198-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.022"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1684\/ejd.2018.3448","article-title":"Assessment of quality of life using Skindex\u201016 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study","volume":"28","author":"Hansson J","year":"2018","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"e_1_2_7_18_1","unstructured":"Appendix B.88. to the vismodegib treatment program for advanced basal cell carcinoma.http:\/\/onkologia\u2010online.pl\/upload\/obwieszczenie\/2016.12.28\/b\/b.88.pdf(last accessed: 31 August 2021)."},{"key":"e_1_2_7_19_1","unstructured":"Eastern Cooperative Oncology Group (ECOG).http:\/\/www.npcrc.org\/files\/news\/ECOG_performance_status.pdf(last accessed: 31 August 2021)."},{"key":"e_1_2_7_20_1","unstructured":"Erivedge (vismodegib) Summary of product characteristics. Last update 11.2019.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/erivedge\u2010epar\u2010product\u2010information_en.pdf(last accessed: 31 August 2021)."},{"key":"e_1_2_7_21_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27 2017 U.S. Department Of Health And Human Serviceshttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf(last accessed: 31 August 2021)."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)31850-0"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3829"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4330"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12526"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0506-z"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2354"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.43"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy495"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.017"},{"key":"e_1_2_7_31_1","first-page":"1","article-title":"Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy","volume":"40","author":"Hall ET","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00126-1"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T19:38:46Z","timestamp":1700336326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/jdv.18070"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18070","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"2021-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}